Pharmaceutical

Orion gets grant for cyp11a1 inhibitors for treating prostate cancer

Discover Orion Corp's groundbreaking patent for novel compounds targeting CYP11A1, offering new hope for treating prostate cancer and other androgen receptor-dependent conditions.

Aug 23, 2024 - 04:00
Discover Orion Corp's groundbreaking patent for novel compounds targeting CYP11A1, offering new hope for treating prostate cancer and other androgen receptor-dependent conditions.
Read the original article

Tags:

Previous Article

OptiBiotix Health gets grant for modified prebiotic oligosaccharides with increa...

Next Article

Ocular Therapeutix gets grant for intracanalicular injectable applicator device ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Call for earlier diagnosis to improve Gaucher disease outcomes

Call for earlier diagnosis to improve Gaucher disease o...

Jan 19, 2024

FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy 

FDA grants RMAT designation to Taysha’s Rett syndrome g...

May 5, 2024

Novartis touts breast cancer win with “landmark” Kisqali results

Novartis touts breast cancer win with “landmark” Kisqal...

Jun 3, 2023